Upgrade to SI Premium - Free Trial

Pacira Pharmaceuticals (PCRX) Data 'Increases Takeout Valuation' - Mizuho

March 1, 2017 10:30 AM
Shares of Pacira Pharmaceuticals (NASDAQ: PCRX) are up 12% following positive Phase IV data from the TKA study. The study ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments FDA Rumors Trader Talk

Next Articles